Business Relations Table - o4.fyi ()

Anmelden Gast|Guest
Beispiel: brt.php?search=wide&s=wide&p=adjective&o=wideness

Domain-Statistiken für "replicor.com"

73
Business Relations
73
Eindeutige Domains
20
Gefundene Einträge
BR-Relations: 73
From Domain Role To Domain Path Aktionen
/news.cgi
/news.cgi
/replicor-to-present-interim-rep-2055-clinical-efficacy-data-at-the-20th-annual-meeting-of-the-apasl-in-beijing-china/
/replicor-to-disclose-interim-rep-2055-clinical-efficacy-data-in-patients-with-chronic-hepatitis-b-at-the-21st-conference-of-the-asian-pacific-association-for-the-study-of-the-liver-apasl-2011/
/replicor-to-disclose-interim-rep-2139-clinical-efficacy-data-in-patients-with-chronic-hepatitis-b-at-the-22nd-conference-of-the-asian-pacific-association-for-the-study-of-the-liver-apasl-2012/
/replicor-to-disclose-interim-rep-2055-2139-clinical-efficacy-data-in-patients-with-chronic-hepatitis-b-at-the-14th-international-symposium-of-viral-hepatitis-and-liver-disease-isvhld-2012/
/replicor-updates-clinical-results-demonstrating-the-achievement-of-therapeutic-vaccine-like-responses-in-patients-with-chronic-hepatitis-b-with-short-term-exposure-to-immunotherapy-in-combination-with/
/replicor-presents-updated-clinical-efficacy-results-in-patients-with-chronic-hepatitis-b-with-short-term-exposure-to-immunotherapy-in-combination-with-rep-2139-ca-and-new-clinical-data-in-patients-rec/
/replicor-presents-clinical-efficacy-and-toxicology-results-in-patients-with-chronic-hepatitis-b-with-short-term-exposure-to-immunotherapy-after-rep-2139-ca-induced-clearance-of-serum-hbsag/
/replicor-to-present-updated-clinical-trial-data-with-combination-treatment-using-its-hbsag-release-inhibitors-in-patients-with-chronic-hepatitis-b-infection-at-the-10th-annual-meeting-of-the-oligonucl/
/replicor-to-present-at-the-2015-lancet-viral-hepatitis-conference/
/replicor-discloses-continued-improvement-of-the-antiviral-response-in-patients-with-hbv-hdv-co-infection-receiving-rep-2139-ca-based-combination-therapy/
/replicor-to-present-pre-clinical-and-clinical-data-on-rep-2139-ca-based-combination-therapy-in-chronic-hbv-hdv-co-infection-at-hepdart-2015/
/replicor-to-present-pre-clinical-and-updated-clinical-data-on-rep-2139-ca-based-combination-therapy-in-chronic-hbv-and-hbv-hdv-co-infection-at-apasl-2016/
/replicor-announces-publication-of-its-rep-101-and-rep-102-studies-demonstrating-the-therapeutic-effect-of-naps-and-the-achievement-of-functional-control-off-treatment-in-human-patients-with-chronic-2/
/replicor-announces-publication-of-its-rep-101-and-rep-102-studies-demonstrating-the-therapeutic-effect-of-naps-and-the-achievement-of-functional-control-off-treatment-in-human-patients-with-chronic-he/
/replicor-to-present-new-hbv-and-hdv-mechanistic-data-for-its-nap-technology/
/replicor-to-present-keynote-presentation-at-the-3rd-world-conference-of-hepatitis-and-liver-diseases-dubai-uae/
/replicor-discloses-high-rates-of-hbsag-loss-with-nap-combination-therapy-at-apasl-2017/
/replicor-showcases-hbv-functional-cure-data-with-rep-2139-mg/